Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
about
Management of gastric and duodenal neuroendocrine tumorsA 15-year experience with gastric neuroendocrine tumors: Does type make a difference?Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.Clinicopathological features of primary gastric neuroendocrine neoplasms: A single-center analysis.
P2860
Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Gastric neuroendocrine tumors: ...... trin/CCK2 receptor antagonist.
@en
type
label
Gastric neuroendocrine tumors: ...... trin/CCK2 receptor antagonist.
@en
prefLabel
Gastric neuroendocrine tumors: ...... trin/CCK2 receptor antagonist.
@en
P2860
P1476
Gastric neuroendocrine tumors: ...... trin/CCK2 receptor antagonist.
@en
P2093
Liv Thomsen
Malcolm Boyce
P2860
P304
P356
10.3109/00365521.2015.1009941
P577
2015-02-09T00:00:00Z